文献速递膀胱癌与上尿路尿路上皮癌

WST-11(TOOKAD可溶性)血管靶向光动力治疗上尿路尿路上皮癌的Ⅰ期试验最终结果

Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
PubMed 文献 · J Urol · 2023-02-01

这项Ⅰ期试验(NCT03617003)纳入19例上尿路尿路上皮癌患者,评估WST-11血管靶向光动力治疗的安全性。14例(74%)接受最大耐受剂量200 mW/cm,其中2例(11%)出现剂量限制性毒性;30天初始治疗反应率94%(完全缓解50%、部分缓解44%),8例接受第二次治疗,最终完全缓解率68%。主要毒性为胁腹痛(79%)和血尿(84%),均为一过性;随访期间未发现与治疗相关的输尿管狭窄。

要点

  • 最大耐受剂量为200 mW/cm,14例(74%)接受该剂量,其中2例(11%)出现剂量限制性毒性。
  • 30天初始治疗反应率94%(完全缓解50%、部分缓解44%),最终完全缓解率68%。
  • 主要毒性为胁腹痛(79%)和血尿(84%),均为一过性;未发现与治疗相关的输尿管狭窄。

核心结论

  • WST-11血管靶向光动力治疗具有可接受的安全性,作为上尿路尿路上皮癌保留肾脏的内镜治疗选择具有较强潜力。
  • 已启动的多中心Ⅲ期ENLIGHTED试验(NCT04620239)预期将为该疗法提供进一步证据。

研究设计与样本

  • Ⅰ期试验(NCT03617003),纳入19例上尿路尿路上皮癌患者,接受最多2次内镜下血管靶向光动力治疗,随访至6个月。
  • 纳入标准为既往内镜治疗失败后存在残留或复发上尿路尿路上皮癌(任何分级/大小),或无法/不愿接受手术切除者。
  • 主要终点为确定激光光通量的最大耐受剂量,采用改良持续重评估方法进行剂量递增(100-200 mW/cm)。
  • 次要终点为治疗有效性,定义为治疗后30天无可见肿瘤且尿细胞学阴性。

主要发现

  • 14例(74%)患者接受最大耐受剂量200 mW/cm,其中2例(11%)出现剂量限制性毒性。
  • 30天初始治疗反应率为94%(完全缓解50%、部分缓解44%)。
  • 8例患者接受第二次治疗,最终观察到的完全缓解率为68%。
  • 主要毒性为胁腹痛(79%)和血尿(84%),均为一过性。
  • 随访期间未发现与治疗相关的输尿管狭窄。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Vascular-targeted photodynamic therapy with the intravascular photosensitizing agent padeliporfin (WST-11/TOOKAD-Soluble) has demonstrated therapeutic efficacy as an ablative treatment for localized cancer with potential adaptation for endoscopic management of upper tract urothelial carcinoma. This Phase I trial (NCT03617003) evaluated the safety of vascular-targeted photodynamic therapy with WST-11 in upper tract urothelial carcinoma. MATERIALS AND METHODS: Nineteen patients underwent up to 2 endoscopic vascular-targeted photodynamic therapy treatments, with follow-up for up to 6 months. Patients who had residual or recurrent upper tract urothelial carcinoma (any grade/size) failing prior endoscopic treatment or unable or unwilling to undergo surgical resection were eligible for inclusion. The primary endpoint was to identify the maximally tolerated dose of laser light fluence. A dose escalation model was employed, with increasing light fluence (100-200 mW/cm) using a modified continual reassessment method. The secondary endpoint was treatment efficacy, defined by absence of visible tumor and negative urine cytology 30 days posttreatment. RESULTS: Fourteen (74%) patients received the maximally tolerated dose of 200 mW/cm, 2 (11%) of whom experienced a dose-limiting toxicity. The initial 30-day treatment response rate was 94% (50% complete, 44% partial). Eight patients underwent a second treatment, with a final observed 68% complete response rate. Leading toxicities were flank pain (79%) and hematuria (84%), which were transient. No ureteral strictures associated with treatment were identified during follow-up. CONCLUSIONS: Vascular-targeted photodynamic therapy with WST-11 has an acceptable safety profile with strong potential as an effective, kidney-sparing endoscopic management option for upper tract urothelial carcinoma. The recently initiated multicenter Phase 3 ENLIGHTED trial (NCT04620239) is expected to provide further evidence on this therapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Yip W, Sjoberg DD, Nogueira LM, et al. Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma. J Urol. 2023. PMID: 36724067. doi:10.1097/JU.0000000000003202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。